The tight correlation between CXCL13 and B-cells and other CSF markers of disease severity makes it a perfect candidate to measure the therapeutic efficacy of the B-cell depleting therapies in MS (ofatumumab, rituximab and ocrelizumab) [186,187,188]. This evidence concerns the gene CXCL13 and myeloid sarcoma.